IL17A and metabolic dysfunction-associated steatotic liver disease: On the other hand, the percentage of IL-17-producing cells among CD4+ T-lymphocytes was twofold more frequent in the total MASLD group [(1.90 (0.83-3.73) vs 0.73 (0.54-1.56), p=0.002], which was noticed at both early [2.22 (1.59-3.66) vs 0.73 (0.54-1.56), p=0.007] and late stages of MASLD (1.70 (0.78-3.96) vs 0.73 (0.54-1.56), p=0.011; Table 2).